Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
EDITORIAL
Lung Cancer and Idiopathic Pulmonary Fibrosis: From Epigenetics to drug therapy
1
Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece
2
Department of Clinical Laboratory Medicine, Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Crete, Greece
3
Department of Thoracic Medicine, Interstitial Lung Disease Unit, University Hospital of Heraklion, Heraklion, Crete, Greece
Corresponding author
Katerina M. Antoniou
Department of Thoracic Medicine and Laboratory of Cellular and Molecular Pneumonology, Medical School, University of Crete, Heraklion 71110 Crete, Greece
Department of Thoracic Medicine and Laboratory of Cellular and Molecular Pneumonology, Medical School, University of Crete, Heraklion 71110 Crete, Greece
Pneumon 2015;28(1):23-25
CONFLICTS OF INTEREST
Nο
REFERENCES (23)
1.
Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Current Opinion in Immunology. 2007;19:694-700.
2.
Schamberger AC, Mise N, Meiners S, Eickelberg O. Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery. Expert Opinion on Drug Discovery. 2014;9:609-28.
3.
Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR155 predicts recurrence and unfavourable survival in non-small cell lung cancer. European Journal of Cancer. 2013;49:604-15.
4.
Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Translational research: The Journal of Laboratory and Clinical Medicine 2011;157:191-9.
5.
Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. The Journal of Experimental Medicine 2010;207:1589-97.
6.
Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism. 2010;62:1733-43.
7.
Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 2011;45:287-94.
8.
Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2010;182:220-9.
9.
Huleihel L, Ben-Yehudah A, Milosevic J, et al. Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts. American Journal of Physiology Lung Cellular and Molecular Physiology 2014;306:L534-42.
10.
Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Reviews Cancer. 2010;10:878-89.
11.
Sarchianaki E, Derdas SP, Ntaoukakis M, et al. Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients. Tumour biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35:3203-9.
12.
Lasithiotaki I, Antoniou KM, Derdas SP, et al. The presence of Merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl-2 genes in non-small cell lung cancer. International Journal of Cancer / Journal International du Cancer. 2013;133:604-11.
13.
Lasithiotaki I, Antoniou KM, Tsitoura E, et al. MicroRNA-21 is significantly overexpressed in Merkel cell polyomavirus-positive non-small cell lung cancer. Int J Mol Med 2014;34:S92-S.
14.
Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire 2015:1-12.
15.
Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2012;186:525- 35.
16.
Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PloS one. 2012;7:e33770.
17.
Antoniou KM, Symvoulakis EK, Margaritopoulos GA, Lionis C, Wells AU. Early diagnosis of IPF: time for a primary-care casefinding initiative? The Lancet Respiratory Medicine. 2014;2:e1.
18.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
19.
Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2142-3.
20.
King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
21.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. The Lancet Oncology 2014;15:143-55.
22.
Grimminger F, Gunther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. ERJ 2015.
23.
Cramer SA, Adjei IM, Labhasetwar V. Advancements in the delivery of epigenetic drugs. Expert Opinion on Drug Delivery 2015:1-12.
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
